PT1680140E - Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof - Google Patents

Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof Download PDF

Info

Publication number
PT1680140E
PT1680140E PT04796034T PT04796034T PT1680140E PT 1680140 E PT1680140 E PT 1680140E PT 04796034 T PT04796034 T PT 04796034T PT 04796034 T PT04796034 T PT 04796034T PT 1680140 E PT1680140 E PT 1680140E
Authority
PT
Portugal
Prior art keywords
fgfr
methods
treatment
growth factor
factor receptor
Prior art date
Application number
PT04796034T
Other languages
Portuguese (pt)
Inventor
Haijun Sun
Juqun Shen
James R Tonra
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PT1680140E publication Critical patent/PT1680140E/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.
PT04796034T 2003-10-16 2004-10-18 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof PT1680140E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51225503P 2003-10-16 2003-10-16

Publications (1)

Publication Number Publication Date
PT1680140E true PT1680140E (en) 2011-05-31

Family

ID=34465334

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04796034T PT1680140E (en) 2003-10-16 2004-10-18 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof

Country Status (13)

Country Link
US (2) US20070274981A1 (en)
EP (3) EP1680140B1 (en)
JP (1) JP4686465B2 (en)
AT (1) ATE506077T1 (en)
CA (2) CA2762955A1 (en)
CY (1) CY1111479T1 (en)
DE (1) DE602004032370D1 (en)
DK (1) DK1680140T3 (en)
ES (1) ES2361917T3 (en)
PL (1) PL1680140T3 (en)
PT (1) PT1680140E (en)
SI (1) SI1680140T1 (en)
WO (1) WO2005037235A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20050282733A1 (en) * 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
PT1680140E (en) 2003-10-16 2011-05-31 Imclone Llc Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
JP4823914B2 (en) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Inhibition of FGFR3 and treatment of multiple myeloma
JPWO2006011686A1 (en) * 2004-07-30 2008-05-01 日本たばこ産業株式会社 Method for screening compound inhibiting cell infection of hepatitis C virus (HCV)
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
JP5792955B2 (en) 2007-10-01 2015-10-14 アイシス ファーマシューティカルズ， インコーポレーテッド Antisense modulation of fibroblast growth factor receptor 4 expression
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
FR2933702A1 (en) * 2008-07-08 2010-01-15 Sanofi Aventis SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR
KR101651703B1 (en) 2008-10-10 2016-08-26 암젠 인크 FGF21 Mutants and Uses Thereof
MX347295B (en) * 2009-03-20 2017-04-20 Amgen Inc Carrier immunoglobulins and uses thereof.
US20120058116A1 (en) * 2009-04-24 2012-03-08 Andrew Beaton Fgfr1c antibody combinations
PT3248610T (en) 2009-05-05 2024-02-01 Amgen Inc Fgf21 mutants and uses thereof
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
CA2764835A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CN102639700A (en) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
EP2679234A3 (en) 2009-12-02 2014-04-23 Amgen Inc. Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
UA109888C2 (en) * 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
AU2014250730B2 (en) * 2009-12-07 2016-10-13 Amgen Inc. Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof
US9517264B2 (en) 2010-04-15 2016-12-13 Amgen Inc. Human FGF receptor and β-Klotho binding proteins
WO2012015674A1 (en) 2010-07-26 2012-02-02 Eli Lilly And Company THERAPEUTIC USES OF AN FGFR1c ANTIBODY
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2653540B9 (en) 2010-12-15 2018-05-16 Inter-University Research Institute Corporation Research Organization of Information and Systems Protein production method
RU2440142C1 (en) * 2011-02-07 2012-01-20 Общество С Ограниченной Ответственностью "Онкомакс" Antibody, stopping or retarding tumour growth (versions), method of suppressing tumour growth, method of diagnosing malignant lesions
SG185832A1 (en) * 2011-05-10 2012-12-28 Agency Science Tech & Res Fgfr1 antibodies and treatment of cancer
KR20140021589A (en) * 2011-04-07 2014-02-20 제넨테크, 인크. Anti-fgfr4 antibodies and methods of use
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
SI2710035T1 (en) 2011-05-16 2017-07-31 F. Hoffmann-La Roche Ag Fgfr1 agonists and methods of use
JP6043347B2 (en) 2011-06-16 2016-12-14 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Antisense regulation of fibroblast growth factor receptor 4 expression
US20140294820A1 (en) * 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
KR20140054268A (en) 2011-08-26 2014-05-08 메리맥 파마슈티컬즈, 인크. Tandem fc bispecific antibodies
HK1213180A1 (en) 2013-03-06 2016-06-30 豪夫迈‧罗氏有限公司 Methods of treating and preventing cancer drug resistance
KR20150143458A (en) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. ANTI-C-MET Tandem Fc Bispecific Antibodies
WO2015017600A1 (en) * 2013-08-01 2015-02-05 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
EP3122776B1 (en) 2014-03-25 2021-04-28 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
AR103442A1 (en) 2015-01-16 2017-05-10 Juno Therapeutics Inc ANTIBODIES AND RECEIVERS OF SPECIFIC CHEMICAL ANTIGENS OF ROR1
JP6695353B2 (en) * 2015-03-25 2020-05-20 ノバルティス アーゲー Formylated N-heterocyclic derivatives as FGFR4 inhibitors
CA2996205A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
CN118725134A (en) 2015-11-08 2024-10-01 豪夫迈·罗氏有限公司 Methods for screening multispecific antibodies
KR102777244B1 (en) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. FGFR2 inhibitors alone or in combination with immunostimulants in cancer treatment
WO2017100642A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
JP7029401B2 (en) 2016-02-02 2022-03-03 フレッド ハッチンソン キャンサー リサーチ センター Anti-ROR1 antibody and its use
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2018095932A1 (en) 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
BR112019023898A2 (en) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc method for treatment of gastric cancer, use of an antibody and composition
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
WO2020048525A1 (en) 2018-09-07 2020-03-12 Generon (Shanghai) Corporation Ltd. Bispecific antigen binding proteins and uses thereof
KR20220119471A (en) * 2019-12-24 2022-08-29 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Novel anti-FGFR2B antibody
US20230052256A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
JP2024517844A (en) 2021-05-04 2024-04-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Multispecific FGF21 receptor agonists and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE120761T1 (en) 1987-05-21 1995-04-15 Creative Biomolecules Inc MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (en) 1990-08-29 2005-08-15 Genpharm Int TRANSGENIC MICE CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69224983T2 (en) * 1991-01-17 1998-07-30 Univ Washington ANTI-GROWTH FACTOR ANTIBODIES IN THE TREATMENT OF Vascular Stenosis
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
PT892789E (en) * 1996-04-12 2002-07-31 Warner Lambert Co IRREVERSIVE INHIBITORS OF TYROSINE KINASES
US6486185B1 (en) * 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
WO2001018210A1 (en) * 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
WO1999024442A1 (en) * 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6514981B1 (en) * 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) * 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO2000027802A1 (en) * 1998-11-12 2000-05-18 Ariad Pharmaceuticals, Inc. Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US20020150575A1 (en) * 2000-01-07 2002-10-17 Cook Mark E. Method to suppress appetite and reduce weight gain
IL151127A0 (en) * 2000-02-15 2003-04-10 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1268544A2 (en) * 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
SE0001285D0 (en) * 2000-04-07 2000-04-07 Elinus Ab Animal and cell models for type II diabetes and their use
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
ES2238463T3 (en) * 2000-08-18 2005-09-01 Agouron Pharmaceuticals, Inc. HYDROXIIMINO-HETEROCICLIC FLUORENS AND USE TO INHIBIT PROTEIN-KINASES.
AR036042A1 (en) * 2001-05-30 2004-08-04 Sugen Inc DERIVATIVES ARALQUILSUFONIL-3- (PIRROL-2-ILMETILIDEN) -2-INDOLINONA, ITS PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF A KINASE PROTEIN
WO2002102854A2 (en) * 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
CA2473810A1 (en) * 2002-01-31 2003-08-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Fgfr agonists
EP2267117A3 (en) * 2002-06-27 2011-07-13 Verva Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
PT1680140E (en) 2003-10-16 2011-05-31 Imclone Llc Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof

Also Published As

Publication number Publication date
WO2005037235A3 (en) 2005-12-22
US20070274981A1 (en) 2007-11-29
US8263074B2 (en) 2012-09-11
WO2005037235A2 (en) 2005-04-28
DK1680140T3 (en) 2011-06-14
ES2361917T3 (en) 2011-06-24
US20120121609A1 (en) 2012-05-17
JP4686465B2 (en) 2011-05-25
EP1680140A4 (en) 2007-12-05
CA2542638A1 (en) 2005-04-28
CY1111479T1 (en) 2015-08-05
CA2762955A1 (en) 2005-04-28
PL1680140T3 (en) 2011-11-30
SI1680140T1 (en) 2011-08-31
EP2060270A3 (en) 2009-12-09
ATE506077T1 (en) 2011-05-15
EP2229955A1 (en) 2010-09-22
EP1680140B1 (en) 2011-04-20
EP1680140A2 (en) 2006-07-19
JP2008501302A (en) 2008-01-24
EP2060270A2 (en) 2009-05-20
DE602004032370D1 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
PL1680140T3 (en) Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
EP2258722A3 (en) Antibodies to fibroblast growth factor-like (FGF-like) polypeptides
HUE048539T2 (en) Method of producing hydrocarbons and oxygen-containing compounds from biomass including fermentation with addition of amino acids (leu, ile, val)
RU2005136013A (en) PHOSPHODYESTERASE 8A
DE60311470D1 (en) PROCESS FOR CLEANING INTERLEUKIN-4 AND ITS MUTINES
WO2002092758A3 (en) Gastrokines and derived peptides including inhibitors
ATE312939T1 (en) METHOD FOR THE RECOMBINANT PRODUCTION OF POLYPEPTIDES
MA High expression level of human epidermal growth factor (hEGF) using a well-designed fusion protein-tagged construct in E. coli.
PL348883A1 (en) Method for carrying out the controlled post−harvest production of proteins in host organisms
AU6839900A (en) Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence
WO2002101069A3 (en) Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
AU2003902414A0 (en) Flowering induction
WO2002083730A1 (en) Novel protein irsal and gene irsal encoding this protein
WO2005047487A8 (en) Motoneuronotrophic factor gene sequences
ATE423200T1 (en) NEW PLEXIN POLYPEPTIDE, DNA CODING IT AND USE THEREOF
AU2003208871A1 (en) Novel retina specific human proteins wdr17, net01, protein kinase a203, protein kinase mak a194, protein a105, protein a106 and c12orf3variants
WO2006073587A3 (en) Hemipteran 5-hydroxytryptamine 7 serotonin receptor
WO2001021794A3 (en) Smad associating polypeptides
UA92449C2 (en) Anti-ngf antibodies and methods using same
RU95114524A (en) DNA, PROTEINS, ANTIBODIES, PLANT, OIL PRODUCTION METHOD, MICROBIAL HOST, DNA FRAGMENT